Zobrazeno 1 - 10 of 245 pro vyhledávání: '"C Felice"'
3
Enhanced neutrophil activity, but not neutrophil extracellular trap markers, is found in patients with symptomatic chronic peripheral arterial disease
Autor: G Buso, E Faggin, A Bressan, S Galliazzo, F Cinetto, C Felice, M Fusaro, A Erdmann, P Pauletto, M Rattazzi, L Mazzolai
Publikováno v: European Heart Journal. 43
Background/Introduction Neutrophil degranulation and neutrophil extracellular traps (NETs) are suggested to play a role in cardiovascular (CV) disease development [1]. Human studies showed that markers of NETs, are increased in patients with severe c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dc0de5d9479f6a37c1cbc66c98db63e4
https://doi.org/10.1093/eurheartj/ehac544.1979
Zobrazit plný text záznamu
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
Akademický článek
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis
Autor: G. Andrisani, E. Gremese, L. Guidi, A. Papa, M. Marzo, C. Felice, D. Pugliese, A. Armuzzi
Publikováno v: Reumatismo, Vol 65, Iss 2, Pp 75-78 (2013)
Inflammatory bowel disease (IBD) is commonly associated with peripheral inflammatory arthritis, and it has been estimated that as many as 12% of IBD patients report these manifestations. However, rheumatoid arthritis (RA) is rarely associated with ul
Externí odkaz: https://doaj.org/article/e55118c5592a46779678e93b1ec3dfc1
Zobrazit plný text záznamu
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
P398 Long term efficacy and safety of ABP, 501 adalimumab biosimilar in inflammatory bowel diseases: preliminary results from the ADASWITCH study
Autor: A Cingolani, C Felice, G Lombardi, F M Onidi, D Checchin, R Colucci, L Grossi, A Ferronato, C Rocchi, M Ascolani, L Binaghi, M F Dore, L Fanini, M Bulajic, G Mocci MD FRCP
Publikováno v: Journal of Crohn's and Colitis. 16:i392-i393
Background Adalimumab (ADA) biosimilars have been developed to have a much lower financial cost than ADA originator. The aim of this study was to evaluate the long term efficacy and safety of Adalimumab biosimilar ABP501 in naïve or switched Inflamm
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6d61b8987360d0c8e6fab2f551258c9d
https://doi.org/10.1093/ecco-jcc/jjab232.525
Zobrazit plný text záznamu
8
P268 IBD and Covid-19 in italy: comparisons between first and second pandemic wave
Autor: C Bezzio, S Costa, A Armuzzi, F Furfaro, S Ardizzone, M Milla, F Bossa, A Orlando, F A Caprioli, F Castiglione, C Viganò, D G Ribaldone, F Zingone, R Monterubbianesi, N Imperatore, S Festa, M Daperno, L Scucchi, A Ferronato, L Pastorelli, P Balestrieri, C Ricci, M Cappello, C Felice, F Coppini, P Alvisi, V Gerardi, A Variola, S Mazzuoli, M V Lenti, S Alessandro, A Buda, F Micheli, V Ciardo, G Casella, A Viscido, G Bodini, G Fiorino, M Vernero, S Saibeni
Publikováno v: Journal of Crohn's and Colitis. 16:i307-i308
Background Coronavirus disease 2019 (COVID-19), had two pandemic waves in 2020, respectively in April and November. In the general population, the first wave has been characterized by a higher prevalence in Northern Italy and a higher mortality rate
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::25d68190304d1c35c2683de71e320d38
https://doi.org/10.1093/ecco-jcc/jjab232.395
Zobrazit plný text záznamu
10
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje